Problems in radiation absorbed dose estimation from positron emitters

The positron emitters commonly used in clinical imaging studies for the most part are short-lived, so that when they are distributed in the body the radiation absorbed dose is low even though most of the energy absorbed is from the positrons themselves rather than the annihilation radiation. These considerations do not apply to the administration pathway for a radiopharmaceutical where the activity may be highly concentrated for a brief period rather than distributed in the body. Thus, high local radiation absorbed doses to the vein for an intravenous administration and to the upper airways during administration by inhalation can be expected. For these geometries, beta point source functions (FPS's) have been employed to estimate the radiation absorbed dose in the present study. Physiologic measurements were done to determine other exposure parameters for intravenous administration of O-15 and Rb-82 and for administration of O-15-CO2 by continuous breathing. Using FPS's to calculate dose rates to the vein wall from O-15 and Rb-82 injected into a vein having an internal radius of 1.5 mm yielded dose rates of 0.51 and 0.46 (rad x g/μCi x h), respectively. The dose gradient in the vein wall and surrounding tissues was also determined using FPS's. Administration of O-15-CO2 by continuous breathing was also investigated. Using ultra-thin thermoluninescent dosimeters (TLD's) having the effective thickness of normal tracheal mucosa, experiments were performed in which 6 dosimeters were exposed to known concentrations of O-15 positrons in a hemicylindrical tracheal phantom having an internal radius of 0.96 cm and an effective length of 14 cm. The dose rate for these conditions was 3.4 (rads/h)/(μCi/cm3). 15 references, 7 figures, 6 tables